Super B and Lithium Werks sign strategic multi-year cell supply agreement to meet soaring demand for lithium batteries
HENGELO, The Netherlands, May 29, 2018 (GLOBE NEWSWIRE) -- Lithium battery specialist Super B (www.super-b.com) and cell supplier Lithium Werks B.V.(www.lithiumwerks.com) have signed a multi-year agreement that will secure worldwide supplies of lithium ion batteries to customers across the world.
Under the agreement, Lithium Werks, a fast-growing lithium battery and portable power solutions group, will gear up its continuous supply of high quality Lithium Werks Nanophosphate Tm Cells, as Super B continues to expand its operations in response to accelerating demand for lithium ion batteries.
"Leading companies in sectors such as automotive, industry, marine and renewable energy are already served by Super B, and their appetite for battery-powered solutions is only getting greater. We are looking forward to supporting Super B as they continue to serve this rapid growth in demand for lithium batteries," said T. Joseph Fisher III, CEO and co-founder of Lithium Werks.
"I have been impressed by Super B's ability to expand quickly in recent years and by its ambition to grow even faster in the years to come. We expect Super B to double in size every year for some time yet and I am happy to say that Lithium Werks has found a strong strategic partner in Super B," Mr Fisher said.
"We are pleased to be partnering with Super B in this long-term strategic alliance as their products and innovations are a perfect match with our proprietary patented Nanophosphate Tm cylindrical cells," Mr Fisher said.
Super B's CEO Henk Kleef said the agreement will benefit its customers.
"This long-term supply agreement for high quality cells from a truly global company like Lithium Werks will further bolster our ability to expand capacity and serve our customers' near insatiable demand for our lithium battery solutions in the coming years," Mr Kleef said.
"Lithium Werks, which has a strong reputation as a provider of Lithium Iron Phosphate cells, modules and scalable power systems, is an ideal partner as we continue to deliver long lasting, safe and reliable energy solutions to our customers," Mr Kleef said.
Both Super B and Lithium Werks specialise in Lithium Iron Phosphate technology, a lithium-ion chemistry that offers high thermal and chemical stability and is seen as the safest lithium-ion technology available today. The strategic cooperation builds on an existing relationship that has now become even stronger.
About Super B
Super B has a strong reputation for developing and producing unique high-end lithium batteries for a variety of industries and applications. Various leading manufacturers and customers in markets such as automotive, recreational vehicles, motorcycles, UPS and marine have experienced the innovative and reliable Super B lithium battery solutions. The Super B solutions are developed and produced in Hengelo, The Netherlands and supported with worldwide regional sales/service centers.
About Lithium Werks
Lithium Werks is a fast-growing global lithium ion battery company with production facilities in China and offices in the USA, the Netherlands, Northern Ireland, Great Britain and Norway. Lithium Werks provides cells, modules, and battery management systems into markets such as material handling, stationary energy storage, medical, and commercial marine.
Lithium Werks Press/Media Relations Telephone +44 (0) 28 9084 5411
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Lithium Werks via Globenewswire
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från GlobeNewswire
Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00 | Pressmeddelande
Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu
Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00 | Pressmeddelande
Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski
Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45 | Pressmeddelande
Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im
Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45 | Pressmeddelande
Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech
Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00 | Pressmeddelande
STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum